Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Treating CLL With Bruton's Tyrosine Kinase Inhibitors : Episode 6

Part 1: Sandoval Sus Discusses Recommended Treatments for a Patient With CLL

December 13, 2021
By Targeted Oncology Staff
Article

During a live virtual event, Jose Sandoval Sus, MD, discussed with participating physicians frontline recommended treatment options for patients with chronic lymphocytic leukemia based on a case scenario, with questions by Targeted Oncology.

Jose Sandoval Sus, MD

Jose Sandoval Sus, MD

Assistant Member

Moffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System

Moffitt Cancer Center

Pembroke Pines, FL

CASE

  • A 71-year-old woman reported symptoms of weight loss and increasing fatigue.
  • Medical history: hypertension, medically controlled
  • Physical examination: axillary lymphadenopathy, spleen palpable about 4 cm below costal margin, ill appearing, and continued only limited daily activity
  • Laboratory results:
    • White blood cell count: 47,000/mm3, 76% lymphocytes
    • Hemoglobin: 8.7 g/dL
    • Platelets count: 115,000/mm3
    • Absolute neutrophil count: 3600/mm3
    • Lactate dehydrogenase: 250 U/L
    • β2-Macroglobulin: 4.3 μg/L
  • Flow cytometry: CD5+, CD20+, CD23+
  • Fluorescence in situ hybridization (FISH): deletion 11q (del[11q])
  • Molecular analysis: IGHV unmutated
  • Bone marrow biopsy: diffuse infiltration by chronic lymphocytic leukemia (CLL), 90%-95%

Targeted OncoloogyTM: What would be the guideline-recommended approach to treating this patient?

SANDOVAL SUS: A quick review of the updated NCCN [National Comprehensive Cancer Network] guidelines gives us a good basic-level understanding of what we have to assess and why it would be useful...for prognostication and to discuss the natural history of CLL with our patients, but also for choosing the best therapy for our patient.1

Important baseline characteristics that we need to assess, especially when we’re going to start treatment on our patients, are the TP53 status and the IGHV region. Then again, when we have mutated TP53; that will be an unfavorable prognosis for patients with CLL, especially if you were planning on giving chemoimmunotherapy. Also, IGHV mutational status, if it’s unmutated, which is a bit counterintuitive, carries an unfavorable prognosis for CLL.

There are some other markers that are surrogates for the mutational status of IGHV, including the percentage of CD38 and Zap70 expression on the CLL cells and CD49d. CD38 was considered unfavorable when it is 30% [or greater], Zap70 when it is 20% or greater, and CD49d equal to or more than 30%. However, nowadays, it’s not straightforward or directly correlated with the mutational status of IGHV. For the most part, we have access to a laboratory where we can send the assessment of the IGHV; that will be the most appropriate way to go.

The fluorescence in situ hybridization, the FISH, on these patients is important to establish a baseline prognosis, especially when we’re going to treat them. More than 80% of our patients with CLL will have some type of alteration on FISH, some type of mutation. The most common, in 55% of our patients, will be the del(11q) as a sole abnormality, which is good because it [indicates] a good prognosis. A neutral prognosis, not good or bad, is trisomy 12. Unfavorable, especially in the era of chemoimmunotherapy, [were] del(11q) and deletion 17p [del(17p)].

A complex karyotype, which is a bit more challenging to obtain in patients with CLL because of the slow growth of those cells, is unfavorable [when there are] 3 or more unrelated chromosome abnormalities in more than 1 cell on karyotype. But these cells need to be stimulated. We usually cannot get the karyotype from peripheral blood. Sometimes we can, but most of the time we cannot, and we usually try to assess that on the bone marrow biopsy. It’s important for some specific instances of treatment of patients with CLL, but it’s not necessary.

At a live virtual meeting, Sandoval Sus asked oncologists what they would offer this patient.

Acalabrutinib
Acalabrutinib + anti-CD20
Ibrutinib
Ibrutinib + anti-CD20
Venetoclax + anti-CD20
Chemoimmunotherapy

What do the NCCN guidelines recommend as therapy for this patient? How would you determine which one is most suitable?

The NCCN guidelines divide the treatment of CLL between patients [who] are frail or have significant comorbidities [versus patients who are considered to be fit based on age]. Usually they put the magic age at 65 years, but we all know, especially in South Florida, that 65 is sometimes just a number.

CLL is a disease of elderly patients, with a median age at diagnosis of 72 years. In those patients, the preferred regimens will be ibrutinib [Imbruvica], acalabrutinib [Calquence], and venetoclax [Venclexta] plus [rituximab (Rituxan), all with a category 1 recommendation].

There are some other recommendations, [such as] single-agent chlorambucil or rituximab; we usually don’t use those treatment strategies. Rituximab can be considered as a single agent if you’re thinking of CLL-related autoimmune hemolytic anemia, especially if you want to pair it with a steroid. The same goes for obinutuzumab [Gazyva] as a single agent, unless the patient is [elderly] and is not interested in any other types of therapies.

In the guidelines, they put the same treatment options for patients in the frail or older group. As other recommendations, the good old FCR—fludarabine, cyclophosphamide, and rituximab, [which] have been proven to be effective chemoimmunotherapy in at least 3 randomized, phase 3 clinical trials—is included. Also, bendamustine plus an anti-CD20 monoclonal antibody and some other options that we don’t use [are listed under other recommendations].

CASE (continued)

The patient was started on ibrutinib 420 mg daily.

Reference

1. NCCN. Clinical Practice Guidelines in Oncology. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2022. Accessed December 9, 2021. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf

Part 1: Frontline Treatment Options for CLL by Risk

Part 2: BTK Inhibitor Options for Frontline CLL

Part 3: Considerations for Venetoclax-Based Therapy in Frontline CLL

Part 1: BTK Inhibitors for CLL in the Second Line

Part 2: Venetoclax and PI3K Inhibition for Relapsed/Refractory CLL

Now Viewing

Part 1: Sandoval Sus Discusses Recommended Treatments for a Patient With CLL

Part 2: Supporting Data for Ibrutinib-Based Regimens in Frontline CLL

Choosing Between Venetoclax or BTK Inhibitors in Frontline CLL

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content

Managing Desmoid Tumors With Molecular Profiling and Recent Guidelines

Managing Desmoid Tumors With Molecular Profiling and Recent Guidelines

Targeted Oncology Staff
July 17th 2025
Article

During a live event, Tony Philip, MD, and participants discussed molecular profiling and active surveillance for desmoid tumor management.

Read More


Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen


Optimizing R/R DLBCL Treatment: Azer-Cel Shows Sustained Responses

Optimizing R/R DLBCL Treatment: Azer-Cel Shows Sustained Responses

Sabrina Serani
July 17th 2025
Article

Promising results emerge from a phase 1b trial of azer-cel, an innovative CAR T-cell therapy, showing high response rates in DLBCL patients.

Read More


Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen


Tailoring CLL Treatment with BTK Inhibitors in a Community Setting

Tailoring CLL Treatment with BTK Inhibitors in a Community Setting

Targeted Oncology Staff
July 16th 2025
Article

During a live event, Andrew H. Lipsky, MD, and participants discussed balancing efficacy, safety, and patient preferences when choosing CLL treatment.

Read More


Awareness of TIL Therapy for Melanoma Is Crucial for Timely Referral

Awareness of TIL Therapy for Melanoma Is Crucial for Timely Referral

Targeted Oncology Staff
July 15th 2025
Article

During a live event, Barbara T. Ma, MD, MS, reviewed guidelines on management and best practices for the use of tumor-infiltrating lymphocytes in melanoma.

Read More

Related Content

Managing Desmoid Tumors With Molecular Profiling and Recent Guidelines

Managing Desmoid Tumors With Molecular Profiling and Recent Guidelines

Targeted Oncology Staff
July 17th 2025
Article

During a live event, Tony Philip, MD, and participants discussed molecular profiling and active surveillance for desmoid tumor management.

Read More


Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen


Optimizing R/R DLBCL Treatment: Azer-Cel Shows Sustained Responses

Optimizing R/R DLBCL Treatment: Azer-Cel Shows Sustained Responses

Sabrina Serani
July 17th 2025
Article

Promising results emerge from a phase 1b trial of azer-cel, an innovative CAR T-cell therapy, showing high response rates in DLBCL patients.

Read More


Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen


Tailoring CLL Treatment with BTK Inhibitors in a Community Setting

Tailoring CLL Treatment with BTK Inhibitors in a Community Setting

Targeted Oncology Staff
July 16th 2025
Article

During a live event, Andrew H. Lipsky, MD, and participants discussed balancing efficacy, safety, and patient preferences when choosing CLL treatment.

Read More


Awareness of TIL Therapy for Melanoma Is Crucial for Timely Referral

Awareness of TIL Therapy for Melanoma Is Crucial for Timely Referral

Targeted Oncology Staff
July 15th 2025
Article

During a live event, Barbara T. Ma, MD, MS, reviewed guidelines on management and best practices for the use of tumor-infiltrating lymphocytes in melanoma.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.